Colorectal liver metastases (CRLM), cancer that has spread from the colon or rectum to the liver, have a deadly reputation.
The U.S. Food and Drug Administration (FDA) has granted traditional approval to Braftovi (encorafenib) for adult patients ...
The BRAFTOVI combination regimen is the only approved targeted regimen for first-line BRAF-V600E mutant metastatic colorectal cancerPivotal results from the Phase 3 portion with mFOLFOX6 of the ...
The FDA has approved the first combination, targeted regimen for previously untreated BRAF V600E mutation-positive metastatic ...
Pfizer Inc. PFE shares are trending on Wednesday following the U.S. Food and Drug Administration’s (FDA) full approval of the ...
Review highlights how transplant oncology is expanding liver transplantation for selected primary and metastatic liver ...
Delcath Systems, Inc.’s Q3 revenue was pressured by weak patient starts, but 2026 growth prospects remain strong. Click for ...
3don MSN
Cancer rates are rising in CT young people. Here’s what doctors say and what you should know
Breta Hasimi struggled to speak when she received the diagnosis of triple-negative breast cancer, one of the most aggressive ...
The FDA has granted full approval to Pfizer Inc.’s Braftovi when used with Eli Lilly’s Erbitux (cetuximab) and ...
The U.S.-based biotech specializes in treating cancers with small molecules, antibody-drug conjugates, and other ...
Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has granted full approval to BRAFTOVI® (encorafenib) in ...
A family say they have been ‘overwhelmed’ by the outpouring of support from strangers as they face one of the most difficult times of their lives ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results